Insider Trading February 19, 2026

Sintx Technologies Director Increases Stake With $9,060 Purchase

Small insider buy, leadership appointment and revised analyst target mark recent company developments

By Derek Hwang SINT
Sintx Technologies Director Increases Stake With $9,060 Purchase
SINT

Sintx Technologies director Mark Lewis Anderson bought 3,000 shares of the company's common stock on February 18, 2026, paying $3.02 per share for a total of $9,060. After the trade, Anderson holds 18,000 shares. Separately, the company announced the appointment of Ryan Elmore as president effective March 16, 2026, and Ascendiant Capital lowered its price target for SINTX from $25 to $16 while retaining a Buy rating, citing valuation considerations.

Key Points

  • Director Mark Lewis Anderson bought 3,000 shares on February 18, 2026 at $3.02 per share, totaling $9,060.
  • After the purchase, Anderson directly owns 18,000 shares of Sintx Technologies.
  • Ryan Elmore will become president on March 16, 2026, bringing more than 15 years of experience in advanced biomaterials and medical device commercialization; he previously served as Core Business Director at Invibio, a division of Victrex plc.
  • Ascendiant Capital cut its price target for SINTX from $25 to $16 but kept a Buy rating, citing valuation considerations and noting remaining upside from the current share price.

Director Mark Lewis Anderson of Sintx Technologies, Inc. purchased 3,000 shares of the company's common stock in a single transaction executed on February 18, 2026. The shares were acquired at $3.02 each, resulting in an aggregate purchase amount of $9,060. Following that transaction, Anderson's direct ownership in Sintx Technologies stands at 18,000 shares.

The company also disclosed a management change and an analyst update in recent announcements. Sintx Technologies has named Ryan Elmore as president, with his appointment taking effect on March 16, 2026. The company noted Elmore brings over 15 years of experience in advanced biomaterials and medical device commercialization. Prior to this appointment, Elmore served as Core Business Director at Invibio, a division of Victrex plc.

In a separate development affecting market expectations, Ascendiant Capital adjusted its price target for SINTX Technologies stock. The firm lowered its target from $25 to $16 but maintained a Buy rating on the shares. Ascendiant cited valuation considerations as the rationale for the reduction and indicated that, despite the lower target, there remains significant upside potential from the current market price.

Taken together, these items outline three recent, distinct developments for Sintx Technologies: an insider purchase by a director, a scheduled leadership transition, and a revised analyst price target. Each of these items was reported with specific metrics and dates: the number of shares acquired, the per-share purchase price, the effective date for the new president, and the before-and-after analyst price targets.

Readers should note that the available disclosures specify the numerical and timing details above without expanding on the strategic rationale behind the insider purchase or the expected operational impact of the leadership change. Likewise, the analyst adjustment was described as driven by valuation considerations and was accompanied by an affirmation of a Buy rating, rather than further quantification of underlying assumptions.


Additional context provided in company communications is limited to the facts set out above.

Risks

  • Valuation uncertainty: Ascendiant Capital lowered its price target from $25 to $16 for valuation reasons, signaling uncertainty about the stock's current valuation - this impacts equity investors and capital markets participants.
  • Leadership transition: The incoming president, effective March 16, 2026, represents a change in executive leadership; the company did not provide further detail on expected operational or strategic effects, creating uncertainty for stakeholders in the medical devices and biomaterials sectors.
  • Limited disclosure: Public statements included specific transaction and appointment data but did not expand on strategic motives or projected outcomes, leaving investors with constrained information when assessing company prospects.

More from Insider Trading

Standex Director Disposes $513K in Stock as Company Posts Q2 Beat Feb 20, 2026 Sonoco Packaging Executive Disposes Small Stake as Company Outlines Multi-Year Earnings Goals Feb 20, 2026 Bank of the James President Buys $25,068 of Stock as Co-Founder Retires Feb 20, 2026 Bank of the James Director Adds $20,412 in Shares; Co-Founder Retires After Long Tenure Feb 20, 2026 Rogers Corp Director Disposes of 8,000 Shares; Stock Near Yearly High After Strong Quarter Feb 20, 2026